Schegerin’s presentation is slated for Thursday, September 10, at 9:45 a.m. EST. The session will focus on the company’s ongoing development of antibodies designed to pair independent disease drivers into single therapeutic agents. The firm’s primary candidate, TALA-125, targets both IL-13 and IL-18 pathways. By combining these clinically validated mechanisms, researchers aim to overcome the efficacy ceilings encountered by current standard-of-care treatments. The strategy targets a broad patient demographic, including those who have shown resistance to existing medical interventions.